Benjamin F. Edwards & Company Inc. Buys 16,858 Shares of Twist Bioscience Co. (NASDAQ:TWST)

Benjamin F. Edwards & Company Inc. lifted its stake in shares of Twist Bioscience Co. (NASDAQ:TWST) by 5,473.4% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 17,166 shares of the company’s stock after purchasing an additional 16,858 shares during the quarter. Benjamin F. Edwards & Company Inc.’s holdings in Twist Bioscience were worth $846,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Victory Capital Management Inc. bought a new stake in shares of Twist Bioscience during the fourth quarter worth $274,000. Charles Schwab Investment Management Inc. increased its holdings in Twist Bioscience by 1.3% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 448,232 shares of the company’s stock worth $16,522,000 after purchasing an additional 5,728 shares in the last quarter. Dimensional Fund Advisors LP increased its holdings in Twist Bioscience by 29.0% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,267,708 shares of the company’s stock worth $46,732,000 after purchasing an additional 284,884 shares in the last quarter. Brown Advisory Inc. bought a new position in Twist Bioscience in the fourth quarter valued at about $225,000. Finally, Norges Bank acquired a new stake in shares of Twist Bioscience during the fourth quarter valued at about $10,766,000.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on TWST. JPMorgan Chase & Co. raised their price objective on shares of Twist Bioscience from $28.00 to $35.00 and gave the company an “underweight” rating in a report on Monday, August 5th. Barclays cut their price target on shares of Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating on the stock in a report on Monday, August 5th. The Goldman Sachs Group increased their price objective on Twist Bioscience from $45.00 to $55.00 and gave the company a “buy” rating in a report on Tuesday, July 9th. Robert W. Baird lifted their target price on Twist Bioscience from $40.00 to $46.00 and gave the stock an “outperform” rating in a report on Monday, August 5th. Finally, TD Cowen upped their price target on Twist Bioscience from $55.00 to $65.00 and gave the company a “buy” rating in a research report on Thursday, June 13th. One equities research analyst has rated the stock with a sell rating and eight have assigned a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $48.22.

Twist Bioscience Price Performance

Shares of Twist Bioscience stock opened at $45.29 on Tuesday. The stock’s 50-day moving average is $47.05 and its 200 day moving average is $43.14. Twist Bioscience Co. has a one year low of $14.42 and a one year high of $60.90. The firm has a market cap of $2.64 billion, a price-to-earnings ratio of -13.48 and a beta of 1.76.

Twist Bioscience (NASDAQ:TWST) last released its quarterly earnings data on Friday, August 2nd. The company reported ($1.47) earnings per share for the quarter, missing the consensus estimate of ($0.76) by ($0.71). The company had revenue of $81.50 million during the quarter, compared to the consensus estimate of $77.40 million. Twist Bioscience had a negative net margin of 74.63% and a negative return on equity of 32.17%. The business’s revenue was up 27.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($1.01) EPS. On average, sell-side analysts expect that Twist Bioscience Co. will post -3.13 EPS for the current fiscal year.

Insider Transactions at Twist Bioscience

In related news, SVP Paula Green sold 1,137 shares of the company’s stock in a transaction that occurred on Monday, August 5th. The stock was sold at an average price of $39.93, for a total transaction of $45,400.41. Following the transaction, the senior vice president now directly owns 88,837 shares of the company’s stock, valued at approximately $3,547,261.41. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In related news, SVP Paula Green sold 1,137 shares of Twist Bioscience stock in a transaction on Monday, August 5th. The shares were sold at an average price of $39.93, for a total value of $45,400.41. Following the completion of the sale, the senior vice president now owns 88,837 shares of the company’s stock, valued at approximately $3,547,261.41. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, COO Patrick John Finn sold 2,207 shares of the company’s stock in a transaction on Tuesday, July 23rd. The stock was sold at an average price of $56.62, for a total transaction of $124,960.34. Following the transaction, the chief operating officer now owns 171,212 shares in the company, valued at approximately $9,694,023.44. The disclosure for this sale can be found here. Insiders have sold 15,125 shares of company stock valued at $664,784 in the last 90 days. 3.92% of the stock is currently owned by corporate insiders.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.